[go: up one dir, main page]

EP1237538A2 - Eine verbesserte pharmazeutische zusammensetzung zur behandlung der erektilen dysfunktion - Google Patents

Eine verbesserte pharmazeutische zusammensetzung zur behandlung der erektilen dysfunktion

Info

Publication number
EP1237538A2
EP1237538A2 EP00990872A EP00990872A EP1237538A2 EP 1237538 A2 EP1237538 A2 EP 1237538A2 EP 00990872 A EP00990872 A EP 00990872A EP 00990872 A EP00990872 A EP 00990872A EP 1237538 A2 EP1237538 A2 EP 1237538A2
Authority
EP
European Patent Office
Prior art keywords
acid
pharmaceutical composition
sildenafil
improved pharmaceutical
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00990872A
Other languages
English (en)
French (fr)
Inventor
Ramakrishna Rao Manager R & D VALLABHANENI (F)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of EP1237538A2 publication Critical patent/EP1237538A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Definitions

  • the present invention relates to an improved pharmaceutical composition containing sildenafil intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes.
  • the composition is also particularly effective in patients with erectile dysfunction due to spinal cord injury.
  • the pharmaceutical composition of the present invention may be in the form of a solution or a colloidal dispersion in a pharmaceutical vehicle.
  • the composition can be filled into specially designed dosing device for nasal administration.
  • Sildenafil has the chemical formula C 22 H 30 N O 4 S
  • Sildenafil is potent and selective inhibitor of type V cyclic guanosine mono phosphodiestrase (cGMP) with utility for the treatment of male erectile dysfunction. Recently, it has been hypothesized that penile erections are dependent on nitric oxide (NO) and its second messenger cGMP. Sildenafil amplifies the neuronal nitric oxide (NO) / cGMP pathway implicated in the relaxation of the corpus cavernosum. The drug is well tolerated orally. Headache, dyspepsia, facial flushing and muscular ache are the common adverse events reported [Steers, W. D. et al. 2 nd Meet Eur. Soc. Impotence Res.
  • cGMP cyclic guanosine mono phosphodiestrase
  • sildenafil citrate (M/s Pfizer Inc.). Sildenafil citrate is soluble in dimethylformamide, sparingly soluble in acetic acid, slightly soluble in alcohol. About 3.5 mg is soluble in water.
  • JP 10298062 a pharmaceutical composition in the form of tablets that rapidly soluble in the oral cavity and manufacturing procedure has been disclosed.
  • WO 9830209 a rapidly releasing and taste masking pharmaceutical composition
  • a core containing Sildenafil an inner coating layer formed of a water soluble polymer and an outer coating layer formed on inner coating containing saliva insoluble polymer and a process for preparing such oral dosage form
  • sildenafil is administered orally about one hour before intercourse. This is a major disadvantage of the oral formulations, creating in convenience to the partners. Rapid onset of action is highly desirable in such therapeutic indication for patients.
  • WO 00/00199 an intranasal dosage unit of cyclic guanosine monophosphate specific phosphodiesterase inhibitors are described which are combined with suitable intranasal carriers having a buffer, surfactant and absorption enhancers, in order to achieve a peak plasma concentration of the inhibitor in less than 1 hour, and desirably with in 30 minutes of administration in mammals.
  • active ingredient is dispersed in a buffer followed by thickening agent, humectant and surfactant are added.
  • the disadvantage associated with this type of suspension formulations is that the dispersed drug particles in the viscous medium may have to over come the resistance caused by the medium to reach onto the surface of the mucous membrane for its dissolution and penetration through the membrane. Further the drug is in solid state with less fluid volume and surface area made available for dissolution and penetration that reduces the absorption of drug compared to solution.
  • the dispersion system may delay onset of action initially, though it prolongs the duration of action due to slow penetration. The delay m the onset of action may cause patient incompliance. Further, the limited solubility of the sildenafil citrate may leads to improper dosing of the formulation.
  • the above patent also claimed an intranasal powder formulation by using sildenafil mesylate and lactose.
  • the composition was milled to an average particles of 20 microns size and filled into a gelatin capsule for use with a commercial nasal device. Inhalation of this powder may cause irritation to the mucous membrane, and absorption of the active ingredient is slow compared to the solution form as described above.
  • WO 9966933 a method for rapidly and reliably delivering sildenafil to the systemic circulation of a patient intranasally in a pharmaceutical composition contained sildenafil or a pharmaceutically acceptable salts and carrier was disclosed.
  • sildenafil citrate was dissolved with the help of mesylic acid and the pH adjusted to 2.8 to 3.0 with sodium hydroxide.
  • a "sildenafil nasal spray solution" containing sildenafil hydrochloride dissolved in phosphate buffer and isotonicity adjusted with sodium chloride.
  • aqueous nasal gel which contains sildenafil hydrochloride, methocel and an acetate buffer. It has also disclosed a composite nasal spray solution containing sildenafil hydrochloride, and apomorphine hydrochloride.
  • the main objective of the present invention is to provide an improved pharmaceutical composition intended for nasal administration for the treatment of male erectile dysfunction due to organic, pyschogenic and mixed causes containing sildenafil for nasal application.
  • Yet another objective of the present invention is to provide an improved pharmaceutical composition in the fo ⁇ of a solution or colloidal dispersion intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes containing sildenafil for nasal application in a suitable pharmaceutical vehicle, comprising of a solvent, co- solvent and / or solubilizing agent, penetration enhancer, stabilising agent, buffering agent, and a tonicity agent; optionally contain an anti-microbial agent and / or viscosity modifying agents.
  • Still another objective of the invention is to provide a method for preparing the improved pharmaceutical composition containing sildenafil in the form of a solution or colloidal dispersion intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes.
  • the present invention is based on our finding that the poorly water soluble sildenafil or its salt, dissolves completely in mild acids such as lactic acid, hydrochloric acid, ascorbic acid, citric acid, succinic acid, maleic acid, orthophosphoric acid or methyl sulfonic acid and the resulting solution when mixed with solubilisers and penetration enhancers such as polyethyleneglycol, propylene glycol, glycerol, ethyl alcohol, purified diethylene glycol monoethyl ether, propyleneglycol monolaurate and the pH is adjusted 3.0 to 8.0 with citrate, acetate or phosphate buffer and tonicity is adjusted with sodium chloride or dextrose or mannitol, the resulting composition acquires unique property of promoting rapid absorption of sildenafil resulting in rapid onset of action when administered through the nasal route due to synergistic activities of the above said components. It was noticed that the free base of sildenafil is preferably more soluble in as
  • lactic acid is more preferable as it is highly biocompatible and is present in organs such as lever, kidney, thymus gland, stratum corneum, human amniotic fluid and other organs and body fluids.
  • the above said pharmaceutical composition has rapid onset of action upon administration through nasal route with out any adverse effects due to the synergistic effect of the ingredients employed in the composition which results in keeping the active ingredient namely sildenafil or its salt in solution or dispersion fo ⁇ and absorption is further promoted by penetration enhancers making it absorb readily when the composition is administered through the nasal route for eliciting the desired therapeutic response.
  • composition can be filled into a suitable container fitted with nasal applicator.
  • the composition can be filled either in multiple dose container fitted with an applicator or "Monospray” (supplied by M/s Valois India Pvt., Ltd., 407, Madhava,Bandra-kurla Complex, Bondra(E), Mumbai- 400 051), filled with single dose of medicament.
  • the present invention provides an improved pharmaceutical composition intended for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes in the form of solution or colloidal dispersion, which comprises solution or colloidal dispersion of Sildenafil or its salt in a "Protogenic" solvent containing solubilisers and penetration enhancers, stabilizing agent, buffering agents and an isotonicity agent, the solution or the dispersion having a pH in the range of 3.0 to 8.0.
  • the solution or the dispersion is stable at room temperature and sub ambient temperatures as well without any precipitation and/or re-crystallisation.
  • the composition is not a mere admixture of the ingredients employed resulting in a composition having the aggregate properties of the said ingredients.
  • the composition in solution form is preferred to the dispersion form as the former has more rapid absorption and onset of action than that of a dispersion form.
  • the pharmaceutical composition so formed is then filled in either a multiple dose containers fitted with a mechanical pump and a nasal applicator with an over cap or a "Monospray" (supplied by M/s Valois India Pvt., Ltd., 407, Madhava, Bandra-kurla Complex, Bondra(E), Mumbai- 400 051), nasal liquid unidose device.
  • the preferred device is "Monospray”.
  • Sildenafil employed in the pharmaceutical composition may be the base or its salt form with organic acids such as citric acid, lactic acid, acetic acid, succinic acid, maleic acid and the like or inorganic acids such as sulphuric acid, hydrochloric acid, orthophosphoric acid etc.
  • the amount of sildenafil or its salt employed in the pharmaceutical composition may range from 2.5 to 25.0% w/v, preferably 5.0 to 20.0% w/v more preferably 7.5 to 15.0% w/v.
  • the pH of the pharmaceutical composition may preferably be in the range of 3.5 to 5.0.
  • the "Protogenic" solvents, which act as proton donors, used m the pharmaceutical composition may be selected from a group of mild acids such as hydrochloric acid, sulphuric acid, lactic acid, solutions of ascorbic acid, citric acid and amphiprotic solvents such as water or their mixtures.
  • the volume of such solvents present in the pharmaceutical composition may range from 10.0 to 80.0%v/v, preferably 20.0 to 60.0% v/v.
  • the co-solvents when used in the pharmaceutical composition may be selected from a group of "Amphiprotic" solvents, which act as both proton acceptors and proton donors such as the alcohols e.g. ethyl alcohol, propylene glycol, glycerol and polyethylene glycols having a nominal molecular weight of 200 - 600 or N- methyl-2-pyrrolidone, which enhances the solubility of sildenafil or its salts by formation of complex.
  • the volume of such co-solvents present in the pharmaceutical composition may range from 1.0 to 50.0% v/v preferably 15.0 to 30.0% v/v.
  • the solubilising agents used in the pharmaceutical composition may be selected from purified diethylene glycol monoethyl ether, cyclodextrins, glycerol monostearate, lecithin, poloxomer, polyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, stearic acid, citric acid, and ascorbic acid and the like; surface active agents such as polysorbates, sorbiton esters, polyvinyl alcohol, benzal konium chloride, benzithonium chloride, cetrimide, docusate sodium, sodium lauryl sulphate, octoxynol and the like or a combination of these.
  • the amount of such solubilising agent present in the pharmaceutical composition may range from 0.01 to 30.0% w/v, preferably 5.0 to 15.0%w/v.
  • solubility enhancers used in the composition may be selected from DL- methionine, caffeine, nicotinamide, vanillin, benzyl alcohol, known in art as solubility enhancers when added to the solutions of other substances.
  • the buffering agent used in the pharmaceutical composition may be selected from hydrochloric acid, sodium acetate, glacial acetic acid, orthophosphoric acid, potassium dihydrogen orthophosphate and the like.
  • the penetration enhancers used in the pharmaceutical composition of the present invention are selected from ethyl alcohol, propylene glycol, N-methyl-2- pyrrolidone, bile salts, cyclodextrins, propyleneglycol monolaurate in combination with purified diethylene glycol monoethyl ether and the like known in the art for intranasal application.
  • the amount of such penetration enhancer present in each ml of the composition may range from 0.1 to 30.0%v/v or w/v, preferably 5.0 to 25.0%v/v or w/v.
  • the stabilizing agent used in the pharmaceutical composition maybe selecte ⁇ from among those substances known in the art such as sodium metabisulphite, sodium bisulphite, disodium EDTA, ascorbic acid etc.
  • the amount of such stabilizing agents present in the composition may range from 0.01 to 0.5% w/v.
  • the pharmaceutical composition may optionally contain anti-microbial agent.
  • the anti-microbial agent may be selected from benzyl alcohol, benzalkonium chloride, phenyl mercuric acetate, phenylethyl alcohol and the like.
  • the amount of such anti-microbial agent may range from 0.001 to 2.0% w/v preferably 0.02 to 0.5%w/v
  • the pharmaceutical composition may also optionally contain a viscosity building agent to increase the viscosity of the composition, there by prolongs the contact time of the composition with the nasal mucosa, preventing its rapid drain to the larynx region of throat.
  • the viscosity building agent may be selected from hydrocolloids such as hydroxypropyl methylcellulose, poly acrylic acid and the like or water soluble polymers such as carbopol, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and various grades of polyvinylpyrrolidone i.e. K-15, K-30, K-60 and K-90 etc.
  • the amount of such viscosity building agent used in the pharmaceutical composition may range from 0.1 to 5.0% /v.
  • the “Monospray” is a nasal liquid unidose device useful in administrating high potency molecules enabling less frequent administration and treatment of crisis conditions.
  • the device comprises an actuator with over cap, spring, piston, dosage chamber and a ball for closing the dosage chamber from rear end after filling with medicine.
  • a “Monospray” with a nominal volume of the dosage chamber in between 50.0 to 150.0 microliters is selected to deliver 2.5 to 37.5mg, preferably 5.0 to 25.0mg, more preferably 7.5 to 15.0 mg of active substance.
  • the percentage of the drug dissolved may range from 2.5 to 25.0%w/v preferably from 5.0 to 15.0%w/v more preferably from 7.5 to 15.0% w/v.
  • the dose required may constitute one or more number of actuations depending on the dosing device used and the concentration of drug present in the formulation.
  • Each ml contains
  • Glacial acetic acid 0.057 % v/v
  • Phenylethyl alcohol 0.500 % v/v
  • Sildenafil citrate is dissolved in lactic acid and pyrogen free water. Phenylethyl alcohol is added as preservative. Sodium acetate and Glacial acetic acid are added to adjust the pH 3.0. Final volume adjusted to 1.0ml with pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
  • Each ml contains
  • Sildenafil citrate is dissolved in mixture of N-methyl-2-pyrrolidone, and pyrogen fee water Benzalkonium chloride solution is added, pH is adjusted to 3.5 with Potassium dihydrogen orthophosphate and Phosphoric acid. Final volume is adjusted to 1.0ml with Pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray" .
  • Each ml contains
  • Sildenafil citrate is dissolved in a mixture of polyethylene glycol. ethyl alcohol and hydrochloric acid. pH is adjusted to 3.0 with sodium hydroxide. Pyrogen free water is added to make up to one ml. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray" .
  • Each ml contains Sildenafil citrate 7.500 % w/v
  • Sildenafil citrate is dissolved in a mixture of propylene glycol, ethyl alcohol and hydrochloric acid. pH is adjusted 3.0 with sodium hydroxide. Pyrogen free water is added to make up the volume to one ml. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
  • Each ml contains Sildenafil citrate 10.000 % w/v Polyethylene glycol - 300 30.000 % v/v
  • Sildenafil citrate is dissolved in a mixture of polyethylene glycol, glycerol, hydrochloric acid. pH is adjusted to 3.2 with sodium hydroxide. Pyrogen free water is added to make up to one ml. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
  • Each ml contains Sildenafil citrate 10.000 % w/v
  • Phenyl ethyl alcohol 0.500 % v/v
  • Sildenafil citrate is dissolved in a mixture of pyrogen free water, purified diethylene glycol monoethyl ether and octoxynol. Disodium EDTA, polyvinylpyrrolidone K-30, Sodium ascorbate and phenyl ethyl alcohol are added to the above solution. pH is adjusted to 4.0 with sodium acetate and glacial acetic acid. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
  • Each ml contains
  • Sildenafil is dissolved in a mixture of pyrogen free water, purified diethylene glycol monoethyl ether. Ascorbic acid, disodium EDTA, Polyvinylpyrrolidone, benzyl alcohol are added under continuous mixing. pH is adjusted to 4.0 with sodium acetate and glacial acetic acid. Final volume adjusted to one ml with pyrogen free water. The resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".
  • Each ml contains Sildenafil citrate 10.000 % w/v
  • Glacial acetic acid 3.100% w/v
  • Phenyl ethyl alcohol 0.500% w/v
  • Sildenafil citrate is dissolved in a mixture of pyrogen free water and hydrochloric acid.
  • Purified diethylene glycol monoethyle ether, disodium EDTA, polyvinylpyrrolidone (K-l 5), propylene glycol and phenyl ethyl alcohol is added under continuous mixing. pH is adjusted to 4.0 with sodium acetate and glacial acetic acid. Final volume is adjusted to one ml with pyrogen free water.
  • the resultant solution is filtered aseptically and filled into containers fitted with a spraying device for nasal application or into a "Monospray".

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP00990872A 1999-11-18 2000-10-24 Eine verbesserte pharmazeutische zusammensetzung zur behandlung der erektilen dysfunktion Withdrawn EP1237538A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INMA112899 1999-11-18
IN1128MA1999 1999-11-18
PCT/IN2000/000105 WO2001035926A2 (en) 1999-11-18 2000-10-24 An improved pharmaceutical composition for treating male erectile dysfunction

Publications (1)

Publication Number Publication Date
EP1237538A2 true EP1237538A2 (de) 2002-09-11

Family

ID=11096782

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00990872A Withdrawn EP1237538A2 (de) 1999-11-18 2000-10-24 Eine verbesserte pharmazeutische zusammensetzung zur behandlung der erektilen dysfunktion

Country Status (4)

Country Link
EP (1) EP1237538A2 (de)
AU (1) AU3048501A (de)
CA (1) CA2391968A1 (de)
WO (1) WO2001035926A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US20100184722A1 (en) 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
US20130143894A1 (en) * 2010-06-07 2013-06-06 vadel Pharma Inc. Oral spray formulations ad methods for administration of sildenafil
CN104822368B (zh) * 2011-12-05 2019-01-11 苏达公司 西地那非口腔喷雾制剂及其给药方法
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
ES2475942B1 (es) * 2013-01-11 2015-04-16 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
FR3008618A1 (fr) * 2013-07-19 2015-01-23 Univ Paris Curie Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine
NO2723977T3 (de) * 2014-03-19 2018-03-10
ES2864099T3 (es) * 2015-04-03 2021-10-13 Benuvia Therapeutics Llc Formulaciones de pulverización sublingual de sildenafilo
CA2994709A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
AU2021280285A1 (en) * 2020-05-26 2023-02-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction
CN114028348B (zh) * 2021-10-09 2022-11-08 南京长澳医药科技有限公司 一种枸橼酸西地那非口腔崩解片及其制备方法
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739417B2 (en) * 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0135926A3 *

Also Published As

Publication number Publication date
CA2391968A1 (en) 2001-05-25
WO2001035926A2 (en) 2001-05-25
AU3048501A (en) 2001-05-30
WO2001035926A3 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
US6200591B1 (en) Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
EP1112075B1 (de) Pharmazeutische zusammensetzungen zur behandlung von erektiler dysfunktion
KR100810872B1 (ko) 감기 치료용 조성물
JP2003501468A (ja) アポモルヒネの経鼻送達
EP1250925B1 (de) Nasenspray enthaltend Ondansetron-hydrochlorid
JPH05194215A (ja) ５−ベンゾイル−２，３−ジヒドロ−１ｈ−ピロリジン−１−カルボン酸を含有する鼻内投与用治療組成物
EP1237538A2 (de) Eine verbesserte pharmazeutische zusammensetzung zur behandlung der erektilen dysfunktion
JPH09507477A (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
KR20020016832A (ko) 모르핀 글루코네이트로 이루어진 조성물 및 방법
US20090246273A1 (en) Ketorolac Sublingual Spray for the Treatment of Pain
JPH10158169A (ja) 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法
HUP0303877A2 (hu) Imidazotriazinon-tartalmú készítmények nazális alkalmazásra
JPH03287535A (ja) プラノプロフェン水溶液
US20080003275A1 (en) Treatment of Premature Ejaculation
US12324811B2 (en) Intranasal formulation
JP2729859B2 (ja) 可逆性熱ゲル化水性医薬組成物
JP2011524366A (ja) 鼻内投与のためのケトロラクの薬学的処方物
WO2000000193A1 (en) Methods and pharmaceutical formulations for preventing and treating motion sickness
EP1136072A1 (de) Zubereitung zur verabreichung in den harnleiter
JPH07215877A (ja) 点鼻液剤
JP2002037735A (ja) カフェイン類の安定化方法および粘膜適用組成物
US7645765B2 (en) Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion
AU2005100183A4 (en) Treatment of premature ejaculation
EP0296227A1 (de) Verabreichung von aminosäuren durch die nase
JP2022501407A (ja) ゾルピデム又はその薬学的に許容される塩の口腔粘膜溶液剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20031110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051122